Oddo BHF - Basic-Fit NV (BFIT) Basic-Fit N.V. : Outperform reiterated following two irrational trading days; TP cut to € 28

Report

Oddo BHF

Robert Jan Vos

Basic-Fit N.V. : Outperform reiterated following two irrational trading days; TP cut to € 28

14/03/2025 1 EN

Underlying

Basic-Fit NV

Basic-Fit NV is an operator of fitness centers based in the Netherlands. The Company operates more than 350 fitness clubs in the Netherlands, Belgium, France and Spain.

See profile

NL0011872650 Euronext Amsterdam Netherlands

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Robert Jan Vos

Other Reports on these Companies

Oddo BHF

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 03/14/2025

2h / 30m 2h / 30m 1 EN

Oddo BHF

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 14/03/2025

2h / 58m 2h / 58m 1 FR

ODDO : Les fondamentaux face à l’incertitude

Les déboires récents de quelques sociétés du secteur (déceptions de CagriSema de Novo, de l’anti-TIGIT de Roche ou investigations en Chine pour AZN) accompagnés de questionnements sur la politique US ont engendré un derating conduisant à une valorisation faciale attractive : PE 26e de 13.2x. Les publications annuelles des 6 large cap Pharma européennes ont été extrêmement rassurantes confirmant les attentes CT et LT du marché. Avec un BPA en croissance moyenne entre 2024 et 2028 de c10%, le PEG sectoriel n’est que de 1.3x. Dans ce contexte, nous privilégions Sanofi en top pick, relevons notre ...

1h / 9m 1h / 9m 1 FR

Team Pharma

Team Pharma

ODDO : Fundamentals vs uncertainty

The recent setbacks for some sector companies (disappointments over Novo Nordisk’s Cagrisema and Roche’s anti-TIGIT or the investigations in China for AZN) along with question marks over US policy have generated a derating leading to a nominally attractive valuations: P/E 2026e of 13.2x. The full-year earnings reports of the six European large cap pharma companies were extremely reassuring, confirming short- and long-term market expectations. With average expected EPS growth between 2024 and 2028 of c10%, the sector PEG is just 1.3x. In this context, we favour Sanofi as our top pick and upgrad...

1h / 9m 1h / 9m 1 EN

Matthias Desmarais

Matthias Desmarais

Oddo’s 2 Weeks Ahead_Vendredi 14 Mars 2025

1h / 33m 1h / 33m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Basic-Fit N.V. : Outperform reiterated following two irrational trading days; TP cut to € 28

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 03/14/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 14/03/2025

ODDO : Les fondamentaux face à l’incertitude

ODDO : Fundamentals vs uncertainty

Oddo’s 2 Weeks Ahead_Vendredi 14 Mars 2025

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe